Literature DB >> 18830724

Assessment of Alzheimer's disease case-control associations using family-based methods.

Brit-Maren M Schjeide1, Matthew B McQueen, Kristina Mullin, Jason DiVito, Meghan F Hogan, Michele Parkinson, Basavaraj Hooli, Christoph Lange, Deborah Blacker, Rudolph E Tanzi, Lars Bertram.   

Abstract

The genetics of Alzheimer's disease (AD) is heterogeneous and remains only ill-defined. We have recently created a freely available and continuously updated online database (AlzGene; http://www.alzgene.org ) for which we collect all published genetic association studies in AD and perform systematic meta-analyses on all polymorphisms with sufficient genotype data. In this study, we tested 27 genes (ACE, BDNF, CH25H, CHRNB2, CST3, CTSD, DAPK1, GALP, hCG2039140, IL1B, LMNA, LOC439999, LOC651924, MAPT, MTHFR, MYH13, PCK1, PGBD1, PRNP, PSEN1, SORCS1, SORL1, TF, TFAM, TNK1, GWA_14q32.13, and GWA_7p15.2), all showing significant association with AD risk in the AlzGene meta-analyses, in a large collection of family-based samples comprised of 4,180 subjects from over 1,300 pedigrees. Overall, we observe significant association with risk for AD and polymorphisms in ACE, CHRNB2, TF, and an as yet uncharacterized locus on chromosome 7p15.2 [rs1859849]. For all four loci, the association was observed with the same alleles as in the AlzGene meta-analyses. The convergence of case-control and family-based findings suggests that these loci currently represent the most promising AD gene candidates. Further fine-mapping and functional analyses are warranted to elucidate the potential biochemical mechanisms and epidemiological relevance of these genes.

Entities:  

Mesh:

Year:  2008        PMID: 18830724      PMCID: PMC2841132          DOI: 10.1007/s10048-008-0151-3

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  30 in total

1.  PBAT: tools for family-based association studies.

Authors:  Christoph Lange; Dawn DeMeo; Edwin K Silverman; Scott T Weiss; Nan M Laird
Journal:  Am J Hum Genet       Date:  2004-02       Impact factor: 11.025

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  The effect of transferrin polymorphisms on iron metabolism.

Authors:  P L Lee; N J Ho; R Olson; E Beutler
Journal:  Blood Cells Mol Dis       Date:  1999 Oct-Dec       Impact factor: 3.039

4.  Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies.

Authors:  L Bertram; D Blacker; A Crystal; K Mullin; D Keeney; J Jones; S Basu; S Yhu; S Guénette; M McInnis; R Go; R Tanzi
Journal:  Exp Gerontol       Date:  2000-12       Impact factor: 4.032

5.  Haplotypes extending across ACE are associated with Alzheimer's disease.

Authors:  Patrick G Kehoe; Hagit Katzov; Lars Feuk; Anna M Bennet; Boo Johansson; Björn Wiman; Ulf de Faire; Nigel J Cairns; Gordon K Wilcock; Anthony J Brookes; Kaj Blennow; Jonathan A Prince
Journal:  Hum Mol Genet       Date:  2003-04-15       Impact factor: 6.150

6.  ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative.

Authors:  D Blacker; J L Haines; L Rodes; H Terwedow; R C Go; L E Harrell; R T Perry; S S Bassett; G Chase; D Meyers; M S Albert; R Tanzi
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

7.  Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.

Authors:  J Hu; A Igarashi; M Kamata; H Nakagawa
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

8.  Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

Authors:  John S K Kauwe; Jun Wang; Kevin Mayo; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  Neurogenetics       Date:  2008-09-24       Impact factor: 2.660

9.  Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions.

Authors:  D A Loeffler; J R Connor; P L Juneau; B S Snyder; L Kanaley; A J DeMaggio; H Nguyen; C M Brickman; P A LeWitt
Journal:  J Neurochem       Date:  1995-08       Impact factor: 5.372

10.  Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease.

Authors:  Akira Yamamoto; Ryong-Woon Shin; Kazuhiro Hasegawa; Hironobu Naiki; Hiroyuki Sato; Fumio Yoshimasu; Tetsuyuki Kitamoto
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

View more
  31 in total

1.  PKNOX2 is associated with formal thought disorder in schizophrenia: a meta-analysis of two genome-wide association studies.

Authors:  Ke-Sheng Wang; Qunyuan Zhang; Xuefeng Liu; Longyang Wu; Min Zeng
Journal:  J Mol Neurosci       Date:  2012-05-31       Impact factor: 3.444

Review 2.  The Vps10p-domain receptor family.

Authors:  Guido Hermey
Journal:  Cell Mol Life Sci       Date:  2009-05-12       Impact factor: 9.261

Review 3.  The genetics and neuropathology of Alzheimer's disease.

Authors:  Gerard D Schellenberg; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2012-05-23       Impact factor: 17.088

4.  Angiotensin-converting enzyme gene polymorphisms and risk for sporadic Alzheimer's disease: a meta-analysis.

Authors:  Xue-Bin Wang; Ning-Hua Cui; Jia-Jia Gao; Xue-Ping Qiu; Na Yang; Fang Zheng
Journal:  J Neural Transm (Vienna)       Date:  2014-05-23       Impact factor: 3.575

5.  Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease.

Authors:  J S K Kauwe; S Bertelsen; K Mayo; C Cruchaga; R Abraham; P Hollingworth; D Harold; M J Owen; J Williams; S Lovestone; J C Morris; A M Goate
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-06-05       Impact factor: 3.568

6.  Rs4878104 contributes to Alzheimer's disease risk and regulates DAPK1 gene expression.

Authors:  Yang Hu; Liang Cheng; Ying Zhang; Weiyang Bai; Wenyang Zhou; Tao Wang; Zhifa Han; Jian Zong; Shuilin Jin; Jun Zhang; Qinghua Jiang; Guiyou Liu
Journal:  Neurol Sci       Date:  2017-04-20       Impact factor: 3.307

7.  Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

Authors:  John S K Kauwe; Jun Wang; Kevin Mayo; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  Neurogenetics       Date:  2008-09-24       Impact factor: 2.660

8.  Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity.

Authors:  Minji Kim; Jaehong Suh; Donna Romano; Mimy H Truong; Kristina Mullin; Basavaraj Hooli; David Norton; Giuseppina Tesco; Kathy Elliott; Steven L Wagner; Robert D Moir; K David Becker; Rudolph E Tanzi
Journal:  Hum Mol Genet       Date:  2009-07-15       Impact factor: 6.150

9.  Genetic polymorphism of interleukin 1β -511C/T and susceptibility to sporadic Alzheimer's disease: a meta-analysis.

Authors:  Hai Yuan; Qing Xia; Pingping Ge; Shaowei Wu
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.